Compare EPR Properties (EPR) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPR Properties vs State Street SPDR S&P Biotech ETF — how do they compare? EPR Properties trades at $61.92 (market cap $4.60B), while State Street SPDR S&P Biotech ETF trades at $151.2. The key difference: EPR Properties pays a 6.19% dividend while State Street SPDR S&P Biotech ETF pays none, and EPR Properties is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals.
| EPR | XBI | |
|---|---|---|
Market Cap | $4.60B | — |
Sector | Real Estate | Broad Market / Factor |
52-Week High | $60.81 | $164.28 |
52-Week Low | $48.71 | $85.16 |
Enterprise Value | $7.66B | — |
Dividend Yield | 6.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPR Properties trades at $61.76, up 3.73% today, with a bullish technical signal from moving averages and recent breakout above key levels. The REIT shows strong profitability with 39.93% net income margin and consistent dividend payments, though Q1 2026 EPS slightly missed expectations. Recent news highlights monthly dividend declarations and a $315 million Six Flags acquisition diversifying its experiential portfolio.
Outlook remains positive with analyst consensus target of $63.25 offering modest upside, supported by 99% occupancy and stable cash flows. Risks include economic sensitivity of entertainment assets and potential interest rate impacts on REIT valuations. The stock presents a balance of income and growth for investors seeking REIT exposure.
XBI (SPDR S&P Biotech ETF) trades at $152.07, down 2.23% today, but maintains a bullish technical outlook with strong momentum indicators. The ETF has gained significant attention with a 17% monthly surge, driven by biotech sector strength and increased M&A activity. Analyst coverage shows a cautious stance with 100% hold rating, reflecting balanced risk-reward assessment amid sector volatility.
The biotech sector shows strong momentum with AI drug discovery advances and record M&A activity ($106 billion in 2026). While XBI offers high-beta exposure to small/mid-cap biotech growth, investors face elevated volatility and regulatory uncertainties. The equal-weight portfolio structure provides diversified exposure to sector innovation but requires tolerance for price swings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
